| Sep 5 |
Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®
|
| Aug 27 |
Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 8 |
Lipocine GAAP EPS of -$0.56 beats by $0.22, revenue of $0.09M misses by $0.2M
|
| Aug 8 |
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024
|
| Aug 8 |
Lipocine: Q2 Earnings Snapshot
|
| Jun 25 |
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study
|
| Jun 10 |
Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024
|
| Jun 6 |
Lipocine (LPCN) Is a Great Choice for 'Trend' Investors, Here's Why
|
| May 28 |
7 Penny Biotech Stocks to Triple Your Investment
|
| May 21 |
Here's Why Momentum in Lipocine (LPCN) Should Keep going
|
